David De Graaf, Ph.D., has served in leadership roles in biotechnology and pharmaceutical firms from the bench to the boardroom. Before joining Syntimmune, David was a Venture Partner at Apple Tree Partners, the lead investor in Syntimmune. Earlier, he was executive chairman and chief executive at Selventa, a firm he successfully rebranded and refocused, growing it to cumulative sales of $35 million. Prior to joining Selventa, de Graaf served as vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim, where he also served as interim head of U.S. research. He also held leadership positions at Pfizer (director of the Systems Biology, Biotherapeutics and BioInnovation Center, head of systems biology) and AstraZeneca (global head of strategic capabilities systems biology, associate director of the computational biology section). He holds a Ph.D. in genetics from the University of Illinois at Chicago, has authored more than 20 peer-reviewed journal articles, and is the inventor on several granted and pending patents.